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LETTER
REPLY TO NATHAMGARI ET AL.:
Nanopore electroporation for intracellular delivery
of biological macromolecules
Yuhong Caoa, Enbo Mab, Stefano Cestellos-Blancoc, Ruoyi Qiud, Yude Sua, Jennifer A. Doudnab,e,f,g,h,
and Peidong Yanga,c,1
We are pleased to see that simulation results by
Mukherjee et al. (1) and Nathamgari et al. (2) are
accordant with our experimental results (3). We also
very much appreciate the detailed simulation study
by Mukherjee et al. (1), specifically, on the prediction
of the existence of an intermediate optimum voltage
for transporting macromolecules. Although we agree
with Nathamgari et al. (2) on the simplicity of the
nanopore-electroporation system in allowing for an
easy adaptation of the technology by the biological
research community, the advantages of using the
nanostraw system (4, 5) and single nanochannels (6)
for uniform dosage control delivery could not be ig-
nored, which would advance the discoveries in the
biomedical research community.
Regarding the so-called minor lapse that Nathamgari
et al. (2) mention in the letter, the up to 50% transfection
efficiency was reported in the 2014 paper (7) that we
have cited, so there is no correction needed. We are
aware that higher transfection efficiency (>70%) is report-
ed in the latest publication by Mukherjee et al. (1). How-
ever, by the time the paper by Mukherjee et al. was
published our paper had already been sent out by PNAS
for external review. We also want to note that before
sending the paper out for publishing we had filed a pat-
ent disclosure that was officially documented on 28 Sep-
tember 2018 (with the priority date of 18March 2018). By
showing the timeline of our publication and invention
disclosure we hope to clarify that our publication repre-
sents our independent research along this direction.
1 P. Mukherjee, S. S. P. Nathamgari, J. A. Kessler, H. D. Espinosa, Combined numerical and experimental investigation of localized
electroporation-based cell transfection and sampling. ACS Nano 12, 12118–12128 (2018).
2 S. S. P. Nathamgari, P. Mukherjee, J. A. Kessler, H. D. Espinosa, Localized electroporation with track-etched membranes. Proc. Natl.
Acad. Sci. U.S.A. 116, 22909–22910 (2019).
3 Y. Cao et al., Nontoxic nanopore electroporation for effective intracellular delivery of biological macromolecules. Proc. Natl. Acad. Sci.
U.S.A. 116, 7899–7904 (2019).
4 X. Xie et al., Nanostraw-electroporation system for highly efficient intracellular delivery and transfection. ACS Nano 7, 4351–4358
(2013).
5 Y. Cao et al., Universal intracellular biomolecule delivery with precise dosage control. Sci. Adv. 4, eaat8131 (2018).
6 P. E. Boukany et al., Nanochannel electroporation delivers precise amounts of biomolecules into living cells. Nat. Nanotechnol. 6, 747–754
(2011).
7 W. Kang et al., Microfluidic device for stem cell differentiation and localized electroporation of postmitotic neurons. Lab Chip 14,
4486–4495 (2014).
aDepartment of Chemistry, University of California, Berkeley, CA 94720; bDepartment of Molecular and Cell Biology, University of California,
Berkeley, CA 94720; cDepartment of Materials Science and Engineering, University of California, Berkeley, CA 94720; dDepartment of Molecular
and Cellular Physiology, Stanford University, Stanford, CA 94705; eHoward Hughes Medical Institute, University of California, Berkeley, CA 94720;
fInnovative Genomics Institute, University of California, Berkeley, CA 94720; gMolecular Biophysics & Integrated Bioimaging Division, Lawrence
Berkeley National Laboratory, Berkeley, CA 94720; and hCalifornia Institute for Quantitative Biosciences, Berkeley, CA 94720
Author contributions: Y.C. and P.Y. designed research; Y.C., E.M., S.C.-B., R.Q., and Y.S. performed research; Y.C. and E.M. analyzed data; and Y.C.,
E.M., J.A.D., and P.Y. wrote the paper.
Competing interest statement: Y.H.C., E.M., J.A.D., and P.Y. are inventors on patent applications (filed by the University of California, Berkeley)
related to the nanopore electroporation (NanoEP) systems and uses thereof. J.A.D. is a cofounder of Caribou Biosciences, Editas Medicine, Intellia
Therapeutics, Scribe Therapeutics, and Mammoth Biosciences and is a member of the board of directors of Driver and Johnson & Johnson
and of the scientific advisory boards for Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Synthego,
Metagenomi, and Inari.
Published under the PNAS license.
1To whom correspondence may be addressed. Email: p_yang@berkeley.edu.
First published October 29, 2019.
www.pnas.org/cgi/doi/10.1073/pnas.1912715116 PNAS | November 12, 2019 | vol. 116 | no. 46 | 22911
L
E
T
T
E
R
D
ow
nl
oa
de
d 
at
 U
ni
ve
rs
ity
 o
f C
al
ifo
rn
ia
 D
ig
ita
l L
ib
ra
ry
 o
n 
Fe
br
ua
ry
 1
2,
 2
02
0 
